ICU Medical, Inc. (NASDAQ:ICUI) Short Interest Update

ICU Medical, Inc. (NASDAQ:ICUI) was the recipient of a large growth in short interest during the month of June. As of June 15th, there was short interest totalling 1,320,000 shares, a growth of 11.9% from the May 31st total of 1,180,000 shares. Currently, 6.2% of the company’s shares are short sold. Based on an average daily volume of 238,900 shares, the short-interest ratio is currently 5.5 days.

Insider Activity at ICU Medical

In related news, COO Christian B. Voigtlander sold 12,539 shares of ICU Medical stock in a transaction that occurred on Thursday, May 30th. The shares were sold at an average price of $103.95, for a total value of $1,303,429.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other ICU Medical news, Director Elisha W. Finney sold 300 shares of the firm’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $104.95, for a total value of $31,485.00. Following the completion of the transaction, the director now owns 2,129 shares of the company’s stock, valued at approximately $223,438.55. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Christian B. Voigtlander sold 12,539 shares of the firm’s stock in a transaction that occurred on Thursday, May 30th. The shares were sold at an average price of $103.95, for a total transaction of $1,303,429.05. The disclosure for this sale can be found here. In the last quarter, insiders sold 14,839 shares of company stock worth $1,546,014. Insiders own 6.70% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in ICUI. UBS Group AG increased its stake in shares of ICU Medical by 241.6% during the third quarter. UBS Group AG now owns 18,864 shares of the medical instruments supplier’s stock worth $2,245,000 after acquiring an additional 13,341 shares during the period. Citigroup Inc. boosted its holdings in ICU Medical by 361.4% during the third quarter. Citigroup Inc. now owns 6,173 shares of the medical instruments supplier’s stock worth $735,000 after buying an additional 4,835 shares in the last quarter. Mariner LLC boosted its holdings in ICU Medical by 169.2% during the third quarter. Mariner LLC now owns 5,476 shares of the medical instruments supplier’s stock worth $652,000 after buying an additional 3,442 shares in the last quarter. Glenmede Trust Co. NA boosted its holdings in ICU Medical by 6.2% during the third quarter. Glenmede Trust Co. NA now owns 8,562 shares of the medical instruments supplier’s stock worth $1,019,000 after buying an additional 499 shares in the last quarter. Finally, Ameriprise Financial Inc. boosted its holdings in ICU Medical by 28.1% during the third quarter. Ameriprise Financial Inc. now owns 324,867 shares of the medical instruments supplier’s stock worth $38,662,000 after buying an additional 71,258 shares in the last quarter. 96.10% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Raymond James raised shares of ICU Medical from a “market perform” rating to an “outperform” rating and set a $135.00 price target for the company in a research report on Monday, June 17th. Needham & Company LLC started coverage on shares of ICU Medical in a research report on Friday, June 21st. They set a “hold” rating for the company. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $127.00.

ICU Medical Stock Performance

NASDAQ ICUI traded up $0.45 during trading on Wednesday, reaching $117.98. The company’s stock had a trading volume of 252,001 shares, compared to its average volume of 278,506. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.09 and a current ratio of 2.61. The firm has a market cap of $2.88 billion, a price-to-earnings ratio of -48.15 and a beta of 0.69. ICU Medical has a twelve month low of $78.28 and a twelve month high of $182.62. The business’s fifty day moving average price is $107.70 and its 200-day moving average price is $102.44.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings data on Tuesday, May 7th. The medical instruments supplier reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.54 by $0.06. ICU Medical had a negative net margin of 2.63% and a positive return on equity of 5.38%. The company had revenue of $566.66 million for the quarter, compared to analyst estimates of $553.15 million. As a group, analysts anticipate that ICU Medical will post 3.5 EPS for the current fiscal year.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.